Abstract 1491P
Background
Palliative care has been proved important for the advanced non-squamous non-small cell lung cancer (NSCLC) patients. Our group previously put forward the concept of early integration of interdisciplinary palliative care model (E-warm), while its roles in patients with driver-gene-negative non-small-cell lung cancer (NSCLC) still remain to be elucidated.
Methods
This study was a two-group parallel 1:1 single-blind single-center randomized controlled trial of combined early palliative care (CEPC) and standard oncological care (SC). Eligible patients were age 18+ years, newly diagnosed with a driver-gene-negative NSCLC, referred for first-/second-line chemotherapy or targeted therapy or immunotherapy, and had an Eastern Cooperative Oncology Group performance status of 0-2. The quality of life was measured with the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale, and the psychological function was measured with the Hospital Anxiety and Depression Scale (HADS), and the Patient Health Questionnaire-9 (PHQ-9). The pain and nutrition levels were respectively evaluated with the Numerical Rating Scale (NRS) and Patient Generated Subjective Global Assessment (PG-SGA). The primary outcome was quality of life (QoL). Secondary outcomes included the overall survival (OS), psychological functioning, pain, and nutrition state. The intention-to-treat method was applied for analysis.
Results
Of the 156 patients enrolled in the CEPC and SC groups, 66 and 90 respectively completed the research. The CEPC group presented higher QoL than the SC group (p < 0.05). Additionally, fewer patients presented depressive symptoms in the CEPC group than in the SC group (p < 0.05), as well as better pain management (p < 0.05), although no significance was observed in nutritional status and OS between CEPC and SC groups.
Conclusions
Combined early palliative care model (E-warm) brings better quality of life in driver-gene-negative NSCLC patients receiving systemic anticancer treatment. E-warm model interventions can be routinely considered in NSCLC patients as the start of systemic anticancer treatment.
Clinical trial identification
ChiCTR2300076684.
Editorial acknowledgement
Legal entity responsible for the study
Chongqing University Cancer Hospital.
Funding
Chongqing Science and Health medical scientific research Project (No.2021MSXM128), Chongqing Talents Program (cstc2021ycjh-bgzxm0256).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10